Ascendant Diagnostics | Tear-Based Breast Cancer Diagnosis
Ascendant Dx is an early stage biotechnology company that was formed in September of 2010 with a focus on developing innovative new approaches to improve the diagnosis of serious disease and conditions.
Ascendant’s first product in development is an in vitro diagnostic assay to detect early stage breast cancer utilizing the proteomic profile present in tears. Implementation of our test in the market place will lead to greater rates of survivability by increasing early detection of breast cancer.
We believe our simple, non-invasive tear-based collection method will rapidly lead to increased participation by individuals who choose not to utilize currently available yearly screening methods.
- Life Sciences
- 535 W. Research Center Blvd.
- Fayetteville, AR 72701
- Omid Moghadam,
- Chief Executive Officer
- Anna Daily, PhD
- Senior Scientist
- Kimberley Fuller,
- Director of Market Research
- and Business Development
Carolina Cruz-Neira and Gareth Morgan were introduced from the Governor's Conference Room at the state Capitol by Gov. Mike Beebe and ARA director Jerry Adams.
The 54-hour event, at which ideas are turned into potential tech-based startup ventures, is scheduled for Sept. 12-14 from the Charles Morgan Auditorium at Acxiom's River Market corporate headquarters.
A unique technology transfer model is helping a Fayetteville company incubate early-stage, high-tech startups and place them on a path to market success.
Good work comes from being authentic, the renowned artist told designers, graphic artists and other "makers of the web" gathered for the 2014 Made by Few tech conference that began Friday at the Argenta Community Theater in downtown North Little Rock.